Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect
chronic lymphocytic leukemia
first‐line therapy
lymphocytes
quality of life
registry
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
26
05
2020
revised:
10
07
2020
accepted:
12
07
2020
entrez:
18
7
2022
pubmed:
26
7
2020
medline:
26
7
2020
Statut:
epublish
Résumé
Health-related quality of life (HRQoL) in patients with chronic lymphocytic leukemia (CLL) is important in guiding treatment decisions. However, the impact of CLL treatment initiation on HRQoL is unclear. We assessed HRQoL using the FACT-Leu and EQ-5D-3L questionnaires in the Connect
Identifiants
pubmed: 35847738
doi: 10.1002/jha2.67
pii: JHA267
pmc: PMC9176138
doi:
Types de publication
Journal Article
Langues
eng
Pagination
188-198Informations de copyright
© 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
J.P.S. has received honoraria/research funding from Abbvie, Acerta, Celgene Corporation, Genentech, Gilead, Janssen, Pharmacyclics and TG Therapeutics. K.C. is employed by Adelphi Values; has received consulting fees from Bristol Myers Squibb, formerly Celgene Corporation, for this work; and has received statistical consulting fees from Amgen and Endomag Ltd. C.N. is employed by Cardinal Health Specialty Solutions; has received research funding from Astellas, Celgene Corporation, Genentech and Seattle Genetics; and has been on advisory boards for AbbVie, Celgene Corporation, Cardinal Health, Genentech and Infinity. N.L. has received research funding from AbbVie, AstraZeneca, Beigene, Genentech, Gilead, Infinity, Juno, Ming, Oncternal, Pronai and TG Therapeutics; has been a consultant for AbbVie, AstraZeneca, Beigene, Genentech, Gilead, Jannsen, Pharmacyclics and Pronai; and has been on an advisory committee for Celgene Corporation. N.E.K. has received research funding from Celgene Corporation, Genentech, Gilead, Hospira and Pharmacyclics; and has been on advisory committees for Celgene Corporation and Gilead. D.L.G. has been a consultant and member of a speakers’ bureau for Celgene Corporation. C.R.F. has received research funding from AbbVie, Acerta, Gilead, Infinity, Janssen, Millennium, Pharmacyclics, Spectrum and TG Therapeutics; has been a consultant for Celgene Corporation, Genentech/Roche, Gilead, Millennium, Optum Rx and Seattle Genetics; and has received honoraria from Celgene Corporation. M.S.D. has served as a consultant for AbbVie, Acerta Pharma, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, Beigene, Genentech, Janssen, MEI Pharma, Pharmacyclics, Research to Practice, Sunesis, Syros Pharmaceuticals, TG Therapeutics and Verastem; and received research funding from Acerta Pharma, Ascentage Pharma, Genentech, MEI Pharma, Pharmacyclics, Surface Oncology, TG Therapeutics and Verastem. P.K., A.S.S., K.S., M.M.G. and E.D.F. are employees of Bristol Myers Squibb and have equity. A.T. is employed by Adelphi Values, an agency that consults with various pharmaceutical companies. A.M. has received research funding from AbbVie, Celgene Corporation, Gilead, Pronai and TG Therapeutics; has been a consultant for AbbVie; and has been a member of a speakers’ bureau for Celgene Corporation.
Références
Br J Haematol. 2007 Oct;139(2):255-64
pubmed: 17897301
Oncology. 2014;87(3):133-47
pubmed: 25012261
Support Care Cancer. 2018 May;26(5):1437-1445
pubmed: 29151174
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
J Clin Oncol. 2007 May 1;25(13):1722-31
pubmed: 17389338
J Clin Oncol. 2007 Nov 10;25(32):5082-6
pubmed: 17991925
Leuk Lymphoma. 2012 Jul;53(7):1289-98
pubmed: 22168274
Br J Haematol. 2016 Dec;175(5):892-903
pubmed: 27861736
Ann Hematol. 2015 Jan;94(1):45-56
pubmed: 25038918
Cancer. 2018 Feb 1;124(3):587-595
pubmed: 29072772
Leuk Lymphoma. 2017 Feb;58(2):399-407
pubmed: 27357445
Leuk Res. 2012 Apr;36(4):438-42
pubmed: 22036634
Support Care Cancer. 2013 Oct;21(10):2853-60
pubmed: 23748484
Health Qual Life Outcomes. 2019 Nov 15;17(1):173
pubmed: 31729982
Br J Haematol. 2008 Dec;143(5):690-7
pubmed: 19016733
Leuk Lymphoma. 2017 Jul;58(7):1598-1606
pubmed: 27830957
Lancet Haematol. 2017 Nov;4(11):e534-e543
pubmed: 28958469
Sex Disabil. 2016;34(4):367-388
pubmed: 27881887
JAMA. 1995 Jan 4;273(1):59-65
pubmed: 7996652
Drugs Context. 2013 Jun 26;2013:212253
pubmed: 24432041
Value Health. 2012 Dec;15(8):1051-8
pubmed: 23244807
Qual Life Res. 2015 Dec;24(12):2895-906
pubmed: 26205768
Acta Oncol. 2016 Sep - Oct;55(9-10):1115-1120
pubmed: 27494089
Curr Med Res Opin. 2016 Aug;32(8):1325-34
pubmed: 27045164
Blood Cancer J. 2018 Oct 3;8(10):93
pubmed: 30283014
Leuk Lymphoma. 2018 Sep;59(9):2075-2084
pubmed: 29295653
J Clin Oncol. 1993 Mar;11(3):570-9
pubmed: 8445433
Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S75-S79
pubmed: 28760305
Curr Med Res Opin. 2014 Nov;30(11):2317-28
pubmed: 25025755
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Ann Oncol. 2015 Sep;26 Suppl 5:v78-84
pubmed: 26314781
Cancer Med. 2019 Jul;8(8):3803-3810
pubmed: 31144473
Eval Health Prof. 2005 Jun;28(2):172-91
pubmed: 15851772
Health Qual Life Outcomes. 2006 Sep 27;4:70
pubmed: 17005038
Health Qual Life Outcomes. 2007 Dec 21;5:70
pubmed: 18154669